 | |
| Clinical data | |
|---|---|
| Other names | Detrifluoromethylfluoxetine |
| ATC code |
|
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H19NO |
| Molar mass | 241.334 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed. [1] [2] [3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine. [1] [2] [3]
See also
- 3-Phenoxy-3-phenylpropan-1-amine (PPPA)
- Development and discovery of SSRI drugs
- Aryloxypropanamine scaffold
References
- ^ a b López-Muñoz F, Álamo C (9 September 2011). "Contribution of Pharmacology to Development of Monoaminergic Hypothesis". In Lopez-Munoz F, Alamo C (eds.). Neurobiology of Depression. CRC Press. pp. 132–. ISBN 978-1-4398-3850-1.
- ^ a b Sneader W (31 October 2005). "Drugs Originating from the Screening of Organic Chemicals". Drug Discovery: A History. John Wiley & Sons. pp. 416–417. doi: 10.1002/0470015535.ch28. ISBN 978-0-470-01552-0.
- ^ a b Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sciences. 57 (5): 411–441. doi: 10.1016/0024-3205(95)00209-o. PMID 7623609.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
|
| |
| Clinical data | |
|---|---|
| Other names | Detrifluoromethylfluoxetine |
| ATC code |
|
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H19NO |
| Molar mass | 241.334 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed. [1] [2] [3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine. [1] [2] [3]
See also
- 3-Phenoxy-3-phenylpropan-1-amine (PPPA)
- Development and discovery of SSRI drugs
- Aryloxypropanamine scaffold
References
- ^ a b López-Muñoz F, Álamo C (9 September 2011). "Contribution of Pharmacology to Development of Monoaminergic Hypothesis". In Lopez-Munoz F, Alamo C (eds.). Neurobiology of Depression. CRC Press. pp. 132–. ISBN 978-1-4398-3850-1.
- ^ a b Sneader W (31 October 2005). "Drugs Originating from the Screening of Organic Chemicals". Drug Discovery: A History. John Wiley & Sons. pp. 416–417. doi: 10.1002/0470015535.ch28. ISBN 978-0-470-01552-0.
- ^ a b Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sciences. 57 (5): 411–441. doi: 10.1016/0024-3205(95)00209-o. PMID 7623609.
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |